Dr. Reardon is Clinical Director at the Center for Neuro-Oncology at Dana-Farber Cancer Center and Associate Professor of Medicine at Harvard Medical School.
Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumor patients. His work includes using innovative clinical therapeutic agents to improve the cure rates in patients with brain and spinal tumors, with particular focus on the use of novel “tumor-targeting” therapeutics, including anti-angiogenesis agents for patients with primary brain tumors. He is also actively involved in clinical trials using immunotherapy, cytotoxins, and convection-enhanced delivery.
Dr. Reardon has co-authored 138 peer-reviewed manuscripts focused on neuro-oncology and 15 additional articles and book chapters. He has also co-edited a neuro-oncology textbook in 2010.
Areas of expertise:
Brain and spinal tumors, Clinical trials in neuro-oncology, Targeted therapies, Anti-angiogenic treatments, Immunotherapy, Convection-enhanced delivery.